Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Authors
Keywords
-
Journal
Journal of Comparative Effectiveness Research
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2018-06-26
DOI
10.2217/cer-2018-0032
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
- (2018) S Novello et al. ANNALS OF ONCOLOGY
- Development and Validation of a High-Quality Composite Real-World Mortality Endpoint
- (2018) Melissa D. Curtis et al. HEALTH SERVICES RESEARCH
- Real-world data for efficient health technology assessment
- (2017) Peter S. Hall EUROPEAN JOURNAL OF CANCER
- Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer
- (2017) James Chih-Hsin Yang et al. Journal of Thoracic Oncology
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
- (2017) Alexandre Vivot et al. Scientific Reports
- Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
- (2017) Jessica Davies et al. PLoS One
- Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer
- (2016) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients WithALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
- (2016) Lucio Crinò et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
- (2016) Sai-Hong Ignatius Ou et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK –Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls
- (2016) Daniel Shao-Weng Tan et al. Journal of Thoracic Oncology
- Alectinib in ALK -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
- (2016) Alice T Shaw et al. LANCET ONCOLOGY
- Characteristics, treatment patterns, and survival among ALK + non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study
- (2016) Jacques Cadranel et al. LUNG CANCER
- Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer
- (2016) Christine Eulenburg et al. PLoS One
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
- (2016) Anthony J Hatswell et al. BMJ Open
- Surgical vs Nonsurgical Treatment Modalities for T3 Glottic Squamous Cell Carcinoma
- (2016) Maha Al-Gilani et al. JAMA Otolaryngology-Head & Neck Surgery
- ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
- (2015) Annie Guérin et al. Cancer Epidemiology
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
- (2015) Peter C. Austin et al. STATISTICS IN MEDICINE
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples
- (2011) Giuseppe Di Lorenzo et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
- (2011) Peter C. Austin MULTIVARIATE BEHAVIORAL RESEARCH
- Weight Trimming and Propensity Score Weighting
- (2011) Brian K. Lee et al. PLoS One
- Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data
- (2010) J. Hadley et al. JNCI-Journal of the National Cancer Institute
- Misunderstandings between experimentalists and observationalists about causal inference
- (2008) Kosuke Imai et al. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started